ViiV, Pfizer and Roche lead list for pharma reputation ranked by patient group, annual survey finds
Patient groups’ view of the pharma industry around the world is improving, according to an annual survey published on Tuesday. Fifty-nine percent of patient groups agreed that the pharma industry’s corporate reputation is “excellent” or “good,” compared to just 50% the year before, according to PatientView’s annual online corporate reputation survey.
Topping the list at No. 1 is HIV-specialty drugmaker ViiV Healthcare which is majority-owned by GlaxoSmithKline with Pfizer and Shionogi shareholders. Following ViiV is Pfizer in the second spot, then Roche and Genentech rank together at No. 3. Gilead and Johnson & Johnson’s Janssen follow them, rounding out the top five.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.